Search
Program Calendar
Browse By Day
Browse By Time
Browse By Person
Browse By Session Type
Personal Schedule
Sign In
Deadlines
Policies
Updating Your Submission
Accessible Presentation
FAQs
Search Tips
About Annual Meeting
Scholars and practitioners have long debated the merits of first-mover advantages (FMA) versus second-mover advantages. One the one hand, benefits derived from FMA include capturing value by appropriating a particular product or process, access to, or ownership of certain assets before competitors have the chance to follow suit. On the other hand, first-movers may suffer from a lack of legitimacy. As a way to alleviate some tension between these views about the advantages of first- versus second-movers, we develop new measures based on whether a product represents a deviation from previous firm products or products on the market. Results from a preliminary study provide clear support for second-mover advantages. Drugs that are both familiar to the firm and exist on the market, but are used in a new way, are more likely to be successful.